|
受注：045-509-1970 |
技術サポート：[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
化学情報
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
| 化学式 | C23H25N3O3S |
|||
| 分子量 | 423.53 | CAS No. | 724741-75-7 | |
| Solubility (25°C)* | 体外 | DMSO | 85 mg/mL (200.69 mM) | |
| Ethanol | 25 mg/mL warmed with 50ºC water bath (59.02 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
溶剤液（一定の濃度）を調合する
生物活性
| 製品説明 | STF-31 is a selective glucose transporter GLUT1 inhibitor. |
|---|---|
| in vitro | STF-31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1. STF-31 significantly inhibits lactate production and extracellular acidification in VHL-deficient cells by about 60%, and decreases glycolysis by decreasing glucose transport. [1] In NAPRT1-expressing cells, STF-31 shows cytotoxicity by inhibiting the enzymatic activity of NAMPT. [2] STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures. [3] |
| in vivo | In mice with VHL-deficient RCC xenografts, a more soluble analog of STF-31 (11.6 mg/kg, i.p.) markedly delays tumor growth. [1] |
プロトコル(参考用のみ)
| 細胞アッセイ | 細胞株 | RCC4/VHL and RCC4 cells |
|---|---|---|
| 濃度 | -- | |
| 反応時間 | 4 d | |
| 実験の流れ | For XTT assays, five thousand cells are plated in 96-well plates. The next day, vehicle (DMSO) or drug is added by serial dilution. Four days later, media are aspirated, XTT solution (0.3 mg/ml of XTT, 2.65 μg/ml N-methyl dibenxopyrazine methyl sulfate in phenol red-free media) is added, and the plates are incubated at 37°C for 1-2 hours. Metabolism of XTT is quantified by measuring the absorbance at 450 nm. IC50s are calculated using linear interpolation. All conditions are measured in triplicate and each experiment is done in duplicate or triplicate. |
|
| 動物実験 | 動物モデル | Mice with VHL-deficient RCC xenografts |
| 投薬量 | 11.6 mg/kg | |
| 投与方法 | i.p. |
参考
|
カスタマーフィードバック
-
Data from [Data independently produced by , , J Virol, 2017, 91(6)]
Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：
| Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function [ Immunity, 2022, 55(1):159-173.e9] | PubMed: 34982959 |
| Core-shell nanosystems designed for effective oral delivery of polypeptide drugs [ J Control Release, 2022, 352:540-555] | PubMed: 36323363 |
| Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis [ Mol Oncol, 2022, 16(15):2861-2880] | PubMed: 35665592 |
| A positive feedback circuit comprising p21 and HIF-1α aggravates hypoxia-induced radioresistance of glioblastoma by promoting Glut1/LDHA-mediated glycolysis [ FASEB J, 2022, 36(3):e22229] | PubMed: 35199870 |
| Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. [ Cell Metab, 2020, 31(3):564-579] | PubMed: 32130883 |
| Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. [ Theranostics, 2020, 6;10(12):5259-5275] | PubMed: 32373211 |
| Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy. [ Int J Nanomedicine, 2020, 24;15:2011-2026] | PubMed: 32273699 |
| Activating Transcription Factor 3 Coordinates Differentiation of Cardiac and Hematopoietic Progenitors by Regulating Glucose Metabolism [ Sci Adv, 2020, 6;6(19):eaay9466] | PubMed: 32494702 |
| mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma. [ Oncogene, 2019, 38(24):4669-4684] | PubMed: 30745576 |
| Monosaccharide Analogues of Anticancer Peptide R-Lycosin-I: Role of Monosaccharide Conjugation in Complexation and the Potential of Lung Cancer Targeting and Therapy. [ J Med Chem, 2019, 62(17):7857-7873] | PubMed: 31276399 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。